Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · 2023 · Pharmaceutical Chemistry Journal. 57(4):523–534
What does this source report?
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% at the reported 14-day assessment. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
- Population and setting
- Mouse pharmacology experiments
- Evidence type
- Animal / experimental
- Preparation
- See the original report; formulation details require verification.
- Source language
- English abstract
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
- An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
- The Russian and English versions are one publication, not independent replication.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Originating research institute’s publication record and abstract checked; full tables not reviewed.
Recorded source-check date: 2026-10-03. This date does not imply a completed systematic review.
Cite and trace this record
Original source: A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al.. Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes Pharmaceutical Chemistry Journal. 57(4):523–534 2023.
Molekul research summary: https://molekul.io/research/adk-camphane-2023. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Chlodantane
N-(adamantan-2-yl)-4-chlorobenzamide, an experimental benzamide from the Russian adamantane programme. Its amide linkage distinguishes it from Bromantane’s arylamine.
Bromantane
An adamantane-derived small molecule, also known as Ladasten. The expanded archive connects clinical asthenia studies, operator experiments and preclinical mechanisms, with model-specific limitations and safety findings.
ADK-918
The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.
Camphane chlorobenzamide
An experimental camphane-based structural analogue of Chlodantane. The cage framework differs from adamantane; this is a chemical candidate, not an established treatment.